Screening a library of expressed cyclic peptides identified clones that reverse the cytotoxicity of α-synuclein in yeast and Caenorhabditis elegans. The results suggest a new approach for intervention in Parkinson's disease, and perhaps a druggable target.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Overington, J.P., Al-Lazikani, B. & Hopkins, A.L. Nat. Rev. Drug Discov. 5, 993–996 (2006).
Reichert, J.M. Nat. Rev. Drug Discov. 2, 695–702 (2003).
Kritzer, J.A. et al. Nat. Chem. Biol. 5, 655–663 (2009).
Scott, C.P. et al. Chem. Biol. 8, 801–815 (2001).
Spillantini, M.G. et al. Nature 388, 839–840 (1997).
Cooper, A.A. et al. Science 313, 324–328 (2006).
Gaeta, A. & Hider, R.C. Br. J. Pharmacol. 146, 1041–1059 (2005).
Gitler, A.D. et al. Nat. Genet. 41, 308–315 (2009).
Knight, Z.A. & Shokat, K.M. Cell 128, 425–430 (2007).
Kinsella, T.M. et al. J. Biol. Chem. 277, 37512–37518 (2002).
C.P.S. is an inventor on US patent 7,354,756 entitled "Intein mediated cyclization of peptides."
About this article
Cite this article
Scott, C. Taking the chemical out of chemical genetics. Nat Chem Biol 5, 609–610 (2009). https://doi.org/10.1038/nchembio0909-609